Bristol Myers’ manufacturing shutdown means lower-than-expected Q3 sales for Abecma

Bris­tol My­ers Squibb and 2sev­en­ty bio said this week that a man­u­fac­tur­ing shut­down will trans­late to low­er-than-ex­pect­ed sales for their CAR-T cell ther­a­py Abec­ma in the third quar­ter.

“We think Q3 sales will be rough­ly in line with Q2, but will re­turn to growth again as we get in­to Q4,” Bris­tol My­ers COO and CEO-des­ig­nate Chris Boern­er said Mon­day at Mor­gan Stan­ley’s health­care con­fer­ence in New York.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.